BioAffinity Competitors
| BIAF Stock | USD 0.85 0.10 13.33% |
BioAffinity Technologies vs Salarius Pharmaceuticals Correlation
Poor diversification
The correlation between bioAffinity Technologies and SLRX is 0.75 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding bioAffinity Technologies and SLRX in the same portfolio, assuming nothing else is changed.
Moving together with BioAffinity Stock
Moving against BioAffinity Stock
| 0.76 | DSGN | Design Therapeutics | PairCorr |
| 0.69 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.55 | ENGN | enGene Holdings Common | PairCorr |
| 0.47 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.44 | 63E | ONWARD MEDICAL BV | PairCorr |
BioAffinity Technologies Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BioAffinity Technologies and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of BioAffinity and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of bioAffinity Technologies does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between BioAffinity Stock performing well and BioAffinity Technologies Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BioAffinity Technologies' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ARTL | 5.44 | (0.75) | 0.00 | (1.99) | 0.00 | 7.86 | 41.63 | |||
| GTBP | 5.44 | 0.03 | 0.00 | 0.12 | 7.79 | 10.84 | 51.03 | |||
| MNDR | 10.33 | 0.07 | 0.00 | (0.18) | 13.16 | 38.58 | 121.66 | |||
| WOK | 11.03 | (3.57) | 0.00 | 7.55 | 0.00 | 20.48 | 121.00 | |||
| CARM | 7.62 | 0.51 | 0.03 | (0.25) | 8.85 | 17.95 | 56.42 | |||
| PBM | 7.85 | (3.89) | 0.00 | (0.61) | 0.00 | 9.41 | 96.64 | |||
| REVB | 4.09 | (1.63) | 0.00 | (0.60) | 0.00 | 6.84 | 35.57 | |||
| PTIX | 7.05 | (1.86) | 0.00 | 1.14 | 0.00 | 14.81 | 58.73 | |||
| LIPO | 8.28 | (0.64) | 0.00 | (0.31) | 0.00 | 17.14 | 94.73 | |||
| SLRX | 6.68 | (2.16) | 0.00 | (0.67) | 0.00 | 16.00 | 61.05 |
Cross Equities Net Income Analysis
Compare bioAffinity Technologies and related stocks such as Artelo Biosciences, GT Biopharma, and Mobile health Network Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARTL | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.2 K) | (29.7 K) | (234.9 K) | (2.3 M) | (2.2 M) | (4.7 M) | (7.4 M) | (10.1 M) | (9.3 M) | (9.8 M) | (8.8 M) | (8.4 M) |
| GTBP | 150 K | (3.7 M) | (5.2 M) | (501 K) | (23.5 M) | (21.5 M) | 9.8 M | (144.2 M) | (259.2 M) | (38.6 M) | (28.3 M) | (58 M) | (20.9 M) | (7.6 M) | (13.2 M) | (11.8 M) | (12.4 M) |
| MNDR | (460.2 K) | (460.2 K) | (460.2 K) | (460.2 K) | (460.2 K) | (460.2 K) | (460.2 K) | (460.2 K) | (460.2 K) | (460.2 K) | (460.2 K) | 68.2 K | (2.4 M) | (15.6 M) | (2.6 M) | (2.3 M) | (2.4 M) |
| WOK | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 6 M | 865.2 K | 112 K | (3.5 M) | (1.1 M) | (965.4 K) | (917.1 K) |
| CARM | (13 M) | (13 M) | (19.8 M) | (19.4 M) | (34.5 M) | (33.5 M) | 1.9 M | (29 M) | (33.7 M) | (107.5 M) | (28.3 M) | (336 K) | (61.2 M) | (86.9 M) | (60.5 M) | (54.4 M) | (57.2 M) |
| PBM | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8 M | (51.2 M) | 1 M | 910.6 K | 956.1 K |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | (3.6 K) | (136.4 K) | (12 M) | (10.8 M) | (120.3 K) | (15 M) | (13.5 M) | (12.9 M) |
| PTIX | (476 K) | (476 K) | (1 M) | (1.1 M) | (1.1 M) | (476 K) | (2.3 M) | (2.3 M) | (2.6 M) | (1.8 M) | (2.5 M) | (4.5 M) | (3.6 M) | (5 M) | (5.5 M) | (5 M) | (5.2 M) |
| LIPO | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.7 K) | (1.9 M) | (2.6 M) | (4.6 M) | (5 M) | (4.5 M) | (4.3 M) |
bioAffinity Technologies and related stocks such as Artelo Biosciences, GT Biopharma, and Mobile health Network Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in bioAffinity Technologies financial statement analysis. It represents the amount of money remaining after all of bioAffinity Technologies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.BioAffinity Technologies Competitive Analysis
The better you understand BioAffinity Technologies competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BioAffinity Technologies' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BioAffinity Technologies' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
BioAffinity Technologies Competition Performance Charts
Five steps to successful analysis of BioAffinity Technologies Competition
BioAffinity Technologies' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by bioAffinity Technologies in relation to its competition. BioAffinity Technologies' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of BioAffinity Technologies in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BioAffinity Technologies' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to bioAffinity Technologies, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your BioAffinity Technologies position
In addition to having BioAffinity Technologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BioAffinity Technologies Correlation with its peers. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Can Biotechnology industry sustain growth momentum? Does BioAffinity have expansion opportunities? Factors like these will boost the valuation of BioAffinity Technologies. Projected growth potential of BioAffinity fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating BioAffinity Technologies demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (13.83) | Revenue Per Share | Quarterly Revenue Growth (0.39) | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies' value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because BioAffinity Technologies' market value can be influenced by many factors that don't directly affect BioAffinity Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between BioAffinity Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioAffinity Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, BioAffinity Technologies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.